S&P 500   4,131.51 (-0.21%)
DOW   32,862.42 (+0.09%)
QQQ   318.43 (-0.71%)
AAPL   164.05 (-0.50%)
MSFT   278.85 (-0.52%)
META   168.78 (-0.86%)
GOOGL   116.83 (-0.40%)
AMZN   138.23 (-0.85%)
TSLA   870.50 (-0.09%)
NVDA   172.46 (-3.07%)
NIO   20.23 (+0.30%)
BABA   91.03 (+0.21%)
AMD   97.85 (-2.22%)
MU   58.65 (-4.56%)
T   18.04 (+0.22%)
CGC   3.14 (-4.27%)
GE   75.18 (+1.10%)
F   15.71 (-0.44%)
DIS   109.65 (+0.49%)
AMC   23.55 (-1.71%)
PYPL   95.47 (-0.82%)
PFE   49.48 (-0.18%)
NFLX   231.58 (-0.82%)
S&P 500   4,131.51 (-0.21%)
DOW   32,862.42 (+0.09%)
QQQ   318.43 (-0.71%)
AAPL   164.05 (-0.50%)
MSFT   278.85 (-0.52%)
META   168.78 (-0.86%)
GOOGL   116.83 (-0.40%)
AMZN   138.23 (-0.85%)
TSLA   870.50 (-0.09%)
NVDA   172.46 (-3.07%)
NIO   20.23 (+0.30%)
BABA   91.03 (+0.21%)
AMD   97.85 (-2.22%)
MU   58.65 (-4.56%)
T   18.04 (+0.22%)
CGC   3.14 (-4.27%)
GE   75.18 (+1.10%)
F   15.71 (-0.44%)
DIS   109.65 (+0.49%)
AMC   23.55 (-1.71%)
PYPL   95.47 (-0.82%)
PFE   49.48 (-0.18%)
NFLX   231.58 (-0.82%)
S&P 500   4,131.51 (-0.21%)
DOW   32,862.42 (+0.09%)
QQQ   318.43 (-0.71%)
AAPL   164.05 (-0.50%)
MSFT   278.85 (-0.52%)
META   168.78 (-0.86%)
GOOGL   116.83 (-0.40%)
AMZN   138.23 (-0.85%)
TSLA   870.50 (-0.09%)
NVDA   172.46 (-3.07%)
NIO   20.23 (+0.30%)
BABA   91.03 (+0.21%)
AMD   97.85 (-2.22%)
MU   58.65 (-4.56%)
T   18.04 (+0.22%)
CGC   3.14 (-4.27%)
GE   75.18 (+1.10%)
F   15.71 (-0.44%)
DIS   109.65 (+0.49%)
AMC   23.55 (-1.71%)
PYPL   95.47 (-0.82%)
PFE   49.48 (-0.18%)
NFLX   231.58 (-0.82%)
S&P 500   4,131.51 (-0.21%)
DOW   32,862.42 (+0.09%)
QQQ   318.43 (-0.71%)
AAPL   164.05 (-0.50%)
MSFT   278.85 (-0.52%)
META   168.78 (-0.86%)
GOOGL   116.83 (-0.40%)
AMZN   138.23 (-0.85%)
TSLA   870.50 (-0.09%)
NVDA   172.46 (-3.07%)
NIO   20.23 (+0.30%)
BABA   91.03 (+0.21%)
AMD   97.85 (-2.22%)
MU   58.65 (-4.56%)
T   18.04 (+0.22%)
CGC   3.14 (-4.27%)
GE   75.18 (+1.10%)
F   15.71 (-0.44%)
DIS   109.65 (+0.49%)
AMC   23.55 (-1.71%)
PYPL   95.47 (-0.82%)
PFE   49.48 (-0.18%)
NFLX   231.58 (-0.82%)
NYSE:PEN

Penumbra - PEN Stock Forecast, Price & News

$169.10
+2.27 (+1.36%)
(As of 08/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$164.77
$173.23
50-Day Range
$116.09
$169.10
52-Week Range
$114.86
$293.20
Volume
627,791 shs
Average Volume
503,516 shs
Market Capitalization
$6.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$218.78

Penumbra MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
29.4% Upside
$218.78 Price Target
Short Interest
Bearish
6.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.89
Upright™ Environmental Score
News Sentiment
0.22mentions of Penumbra in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$57,968 Sold Last Quarter
Proj. Earnings Growth
445.45%
From $0.22 to $1.20 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.55 out of 5 stars

Medical Sector

144th out of 1,098 stocks

Surgical & Medical Instruments Industry

13th out of 112 stocks

PEN stock logo

About Penumbra (NYSE:PEN) Stock

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Penumbra Stock Up 1.4 %

Penumbra stock traded up $2.27 during mid-day trading on Monday, hitting $169.10. The company had a trading volume of 627,791 shares, compared to its average volume of 301,882. The stock has a market cap of $6.37 billion, a price-to-earnings ratio of -325.19 and a beta of 0.73. Penumbra has a 1 year low of $114.86 and a 1 year high of $293.20. The company has a quick ratio of 2.90, a current ratio of 4.93 and a debt-to-equity ratio of 0.03. The business has a fifty day moving average of $132.45 and a 200 day moving average of $173.66.

Penumbra (NYSE:PEN - Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.07. The company had revenue of $208.30 million for the quarter, compared to analyst estimates of $206.24 million. Penumbra had a negative net margin of 2.40% and a positive return on equity of 0.97%. The firm's revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.21 earnings per share. On average, sell-side analysts expect that Penumbra will post 0.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Truist Financial reduced their price target on shares of Penumbra to $180.00 in a research report on Friday, July 22nd. Deutsche Bank Aktiengesellschaft cut their target price on shares of Penumbra from $250.00 to $163.00 in a research note on Thursday, July 21st. TheStreet lowered shares of Penumbra from a "c-" rating to a "d+" rating in a research note on Tuesday, July 12th. Citigroup cut their target price on shares of Penumbra from $280.00 to $220.00 in a research note on Tuesday, May 17th. Finally, Wells Fargo & Company cut their target price on shares of Penumbra from $321.00 to $265.00 in a research note on Wednesday, May 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $218.78.

Insider Transactions at Penumbra

In other news, Director Thomas Wilder sold 248 shares of the firm's stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $123.64, for a total transaction of $30,662.72. Following the transaction, the director now directly owns 462 shares in the company, valued at $57,121.68. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 451 shares of company stock worth $57,968. Insiders own 5.50% of the company's stock.

Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

PEN Stock News Headlines

Penumbra (NYSE:PEN) Trading Up 10.5% After Strong Earnings
Penumbra (NYSE:PEN) Shares Up 10.5% on Strong Earnings
Penumbra (PEN) to Release Earnings on Thursday
TheStreet Downgrades Penumbra (NYSE:PEN) to D+
See More Headlines
Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

PEN Company Calendar

Last Earnings
8/04/2022
Today
8/09/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Employees
3,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$218.78
High Stock Price Forecast
$300.00
Low Stock Price Forecast
$163.00
Forecasted Upside/Downside
+29.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$5.28 million
Pretax Margin
-4.89%

Debt

Sales & Book Value

Annual Sales
$747.59 million
Cash Flow
$1.16 per share
Book Value
$25.53 per share

Miscellaneous

Free Float
35,606,000
Market Cap
$6.37 billion
Optionable
Optionable
Beta
0.73

Key Executives














PEN Stock - Frequently Asked Questions

Should I buy or sell Penumbra stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PEN shares.
View PEN analyst ratings
or view top-rated stocks.

What is Penumbra's stock price forecast for 2022?

9 brokerages have issued 12-month target prices for Penumbra's shares. Their PEN share price forecasts range from $163.00 to $300.00. On average, they anticipate the company's share price to reach $218.78 in the next year. This suggests a possible upside of 29.4% from the stock's current price.
View analysts price targets for PEN
or view top-rated stocks among Wall Street analysts.

How has Penumbra's stock performed in 2022?

Penumbra's stock was trading at $287.32 at the beginning of 2022. Since then, PEN shares have decreased by 41.1% and is now trading at $169.10.
View the best growth stocks for 2022 here
.

When is Penumbra's next earnings date?

Penumbra is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our PEN earnings forecast
.

How were Penumbra's earnings last quarter?

Penumbra, Inc. (NYSE:PEN) released its earnings results on Thursday, August, 4th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.07. The firm earned $208.30 million during the quarter, compared to analysts' expectations of $206.24 million. Penumbra had a positive trailing twelve-month return on equity of 0.97% and a negative net margin of 2.40%. The business's quarterly revenue was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.21 earnings per share.

What guidance has Penumbra issued on next quarter's earnings?

Penumbra issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $860.00 million-$875.00 million, compared to the consensus revenue estimate of $869.01 million.

What is Adam Elsesser's approval rating as Penumbra's CEO?

57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), Boeing (BA) and DexCom (DXCM).

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

Who are Penumbra's major shareholders?

Penumbra's stock is owned by a variety of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (3.38%), TD Asset Management Inc. (0.16%), AEGON ASSET MANAGEMENT UK Plc (0.14%), State Board of Administration of Florida Retirement System (0.13%), Retirement Systems of Alabama (0.12%) and Trillium Asset Management LLC (0.11%). Insiders that own company stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Coyne David, Don W Kassing, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju, Surbhi Sarna and Thomas Wilder.
View institutional ownership trends
.

How do I buy shares of Penumbra?

Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Penumbra's stock price today?

One share of PEN stock can currently be purchased for approximately $169.10.

How much money does Penumbra make?

Penumbra (NYSE:PEN) has a market capitalization of $6.37 billion and generates $747.59 million in revenue each year. The company earns $5.28 million in net income (profit) each year or ($0.52) on an earnings per share basis.

How many employees does Penumbra have?

Penumbra employs 3,800 workers across the globe.

How can I contact Penumbra?

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The official website for the company is www.penumbrainc.com. The company can be reached via phone at (510) 748-3200, via email at investors@penumbrainc.com, or via fax at 510-748-3232.

This page (NYSE:PEN) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.